MCF-7 Xenograft Model Service for Breast Cancer

The MCF-7 xenograft model delivers a validated in vivo translational platform designed to evaluate candidate therapies targeting hormone-receptor-positive (ER+), luminal-type breast cancers under strictly controlled hormonal environments. Alfa Cytology provides a comprehensive, end-to-end MCF-7 xenograft model service, integrating fully authenticated cellular assets with standardized procedural and exogenous estrogen-supplementation protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MCF-7 Xenograft Model for Breast Cancer

The MCF-7 cell line is the most widely characterized human mammary carcinoma model, clinically and scientifically recognized as the gold standard for studying hormone-dependent, luminal A subtype breast cancer. Originally isolated from the pleural effusion of a patient with metastatic breast adenocarcinoma, MCF-7 molecularly expresses high levels of estrogen receptor alpha and progesterone receptor (PR), while lacking human epidermal growth factor receptor 2 (HER2) amplification. This distinct profile makes the MCF-7 model an indispensable preclinical test matrix for validating selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), aromatase inhibitors, and emerging combination therapies designed to overcome endocrine resistance.

When established in vivo as a xenograft in immunocompromised mice, MCF-7 cells exhibit unique, hormone-dependent growth characteristics. Unlike triple-negative or hormone-independent lines, robust tumor propagation in vivo requires continuous, controlled supplementation with exogenous 17β-estradiol, mirroring the systemic endocrine drive found in clinical luminal breast cancer patients.

Fig 1. Schematic summary of metabolic and transcriptome alterations in MCF-7 breast cancer cells treated with ribitol. (Tucker JD, et al., 2022)

Cell Line Information: MCF-7

The MCF-7 cell line maintains a stable epithelial monolayer morphology in vitro and reliably preserves its hormone receptor profiles and endocrine sensitivity signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MCF-7 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, 17β-estradiol supplementation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for ER/PR status and PK/PD profiling. Leveraging our expertise in hormone-dependent luminal breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MCF-7 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MCF-7 xenograft model:

• Cell Culture & Quality Control: MCF-7 cells are cultivated in cell-bank-certified growth media supplemented with authenticated insulin resources. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity before inoculation.
• Host Adaptation & Estrogen Priming: Standardized immunocompromised mice are selected and pre-implanted with controlled-release 17β-estradiol pellets. Animals are acclimated to controlled facility parameters to ensure baseline physiological and hormonal stability.
• Precision Inoculation: A calibrated suspension of MCF-7 cells is prepared and blended with a verified biological matrix carrier to optimize cell viability in a hormone-dependent environment. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous hormonal monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MCF-7 Xenograft Model Construction Workflow

Case Study - MCF-7 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MCF-7 xenograft model was successfully utilized to evaluate the efficacy of a next-generation selective estrogen receptor degrader (SERD) candidate targeting hormone-receptor-positive breast cancer. Under optimized conditions featuring calibrated 17β-estradiol supplementation, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent primary tumor growth inhibition and marked receptor down-regulation in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your hormone-dependent luminal breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation and hormone-supplementation protocols, ensuring uniform tumor growth and minimized variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, target receptor expression analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against hormone-dependent, luminal breast cancer using the robust MCF-7 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.